Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$24 Mln
P/E Ratio
--
P/B Ratio
9.29
Industry P/E
--
Debt to Equity
0
ROE
-24.78 %
ROCE
--
Div. Yield
0 %
Book Value
0.11
EPS
--
CFO
$-18.68 Mln
EBITDA
$-38.95 Mln
Net Profit
$-29.03 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
| -16.68 | -7.42 | -9.10 | -25.38 | -25.31 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
|
|---|---|
|
Neurosense Therapeutics (NRSN)
| -35.66 |
|
S&P Small-Cap 600
| 13.89 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.22 | 25.43 | -- | -79.46 | |
| 1.48 | 138.40 | -- | -23.63 | |
| 2.40 | 109.01 | -- | -103.34 | |
| 9.87 | 466.01 | -- | 342.83 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead... product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. Read more
Chief Financial Officer
Mr. Or Eisenberg
Chief Financial Officer
Mr. Or Eisenberg
Headquarters
Herzliya
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Neurosense Therapeutics Ltd (NRSN) stood at $ 9 Mln as on 31-Mar-25
The share price of Neurosense Therapeutics Ltd (NRSN) is $1.00 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Neurosense Therapeutics Ltd (NRSN) has given a return of -25.31% in the last 3 years.
Neurosense Therapeutics Ltd (NRSN) has a market capitalisation of $ 24 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Neurosense Therapeutics Ltd (NRSN) is 9.29 times as on 25-Apr-2025, a 157% premium to its peers’ median range of 3.61 times.
Since, TTM earnings of Neurosense Therapeutics Ltd (NRSN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neurosense Therapeutics Ltd (NRSN) and enter the required number of quantities and click on buy to purchase the shares of Neurosense Therapeutics Ltd (NRSN).
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
The CEO & director of Mr. Or Eisenberg. is Neurosense Therapeutics Ltd (NRSN), and CFO & Sr. VP is Mr. Or Eisenberg.
There is no promoter pledging in Neurosense Therapeutics Ltd (NRSN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
48
|
|
|
15
|
|
|
8
|
|
|
5
|
| Neurosense Therapeutics Ltd (NRSN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Neurosense Therapeutics Ltd (NRSN) was $0 Mln.
$0.00
(
